Electromagnetic Positioning-Assisted Ultrasound Guidance in Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · May 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to perform a procedure called Transjugular Intrahepatic Portosystemic Shunt (TIPS) to help patients with portal hypertension, a condition that can cause complications in the liver. The trial will use a special tool called the Imedis9000 magnetic navigation system, which helps doctors accurately guide the needle used in the procedure. This technology aims to make the process safer and quicker by reducing the number of needle insertions needed and improving the chances of a successful outcome.

To participate in this trial, patients must be 18 years or older and need TIPS for various serious liver-related issues, such as bleeding or fluid buildup due to liver disease. However, certain health conditions, like severe heart problems or infections, may prevent someone from joining. Participants will receive the TIPS procedure with the guidance of the Imedis9000 system and will be monitored for how well it works and any side effects. If you or a loved one is considering this trial, it’s important to discuss it with a doctor to see if it’s a good fit.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age≥18 years old;
• • Including but not limited to patients requiring TIPS for: acute esophageal/gastric variceal bleeding, portal hypertensive gastropathy, cirrhotic ascites, cirrhotic hydrothorax, hepatorenal syndrome, Budd-Chiari syndrome, atypical portal hypertension, portal vein thrombosis, prevention of recurrent esophageal/gastric variceal bleeding, or prevention of recurrent ectopic variceal bleeding;
• • Deemed by clinicians to require Transjugular Intrahepatic Portosystemic Shunt (TIPS)
• • Voluntarily signed informed consent form
• Exclusion Criteria:
• • Severe right heart failure, congestive heart failure (ejection fraction \<40%), or severe valvular heart disease;
• • Persistent severe pulmonary hypertension (mean pulmonary artery pressure \>45 mmHg) despite treatment;
• • Uncontrolled systemic infection or inflammation;
• • Hepatic encephalopathy stage III-IV;
• • Presence of cardiac pacemaker, metallic implants, or other conditions susceptible to electromagnetic interference;
• • Pregnancy or lactation;
• • Poor visualization of the portal venous system on ultrasound;
• • Investigator-determined unsuitability for study participation.